retatrutide case study VisualAbstract: reduces body weight by 17.5% in patients with obesity CAS 2381089-83-2 (Retatrutide) - BOC

SELECT enrolled patients without diabetes who had established cardiovascular disease and obesity, and semaglutide 2.4 mg reduced MACE by 20%

Strauss AS, Peters S, Boland W, Burse A

Given that up to 50 million people experience acne in the United States alone, science has put a lot of resources into figuring out treatments that can help

If you change the stack, the ratio, and the cadence simultaneously, your research data becomes nearly impossible to interpret

However, over the next year, initiation slowed and even reversed: with first-time prescribing rates declining 31% by June 2025, reflecting an average month-over-month decrease of 0.004 percentage points